Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Natural killer cell transcriptomics following vaccinia virus infection of mice

ABSTRACT: RNA-seq analysis identified differentially regulated genes in purified NK cells isolated from naïve mice or those vaccinated with vaccinia virus. DEGs were compared with

ORGANISM(S): Mus musculus

PROVIDER: GSE225180 | GEO | 2023/02/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Natural killer cell transcriptomics following vaccinia virus infection of mice

Project description:Natural killer cell transcriptomics following vaccinia virus infection of mice

| PRJNA934308 | ENA

Tumor-targeting and cytokine-armed vaccinia virus promotes cytotoxicity towards pancreatic carcinoma cells via activation of human intermediary CD56dimCD16dim natural killer cells.

Project description:Pancreatic ductal adenocarcinoma (PDAC) remains a particularly aggressive disease with few effective treatments. The PDAC tumor immune microenvironment (TIME) has been characterized as immune suppressed. Oncolytic viruses can increase tumor antigenicity via immunogenic cell death (ICD). In this study, tumor-targeting and cytokine-armed vaccinia viruses (vvDD, vvDD-IL2, vvDD-IL15) were used to infect carcinoma cell lines as well as patient-derived primary PDAC cells. In co-culture experiments we tested the cytotoxic response and the activation of human natural killer-(NK-)cells during the oncolytic process.

2024-09-20 | PXD048276 | Pride

Antibody profiling of smallpox vaccinees with/without a 'take' using custom vaccinia virus proteome microarrays

Project description:Successful vaccination against smallpox with conventional vaccinia virus is usually determined by the development of a vesicular skin lesion at the site of vaccinia inoculation, called a ‘take’. Although previous vaccination is known to be associated with attenuation of the take, the immunology that underlies a no-take in vaccinia-naïve individuals is not well understood. We hypothesized that antibody profiling of individuals before and after receiving vaccinia would reveal differences between takes and no-takes that may help better understand the phenomenon. Using vaccinia proteome microarrays and recombinant protein ELISAs we first examined the antibody response in vaccinia-naïve individuals that failed to take after receiving different doses of the replication competent smallpox vaccines, DryVax® and APSV. Most that received diluted vaccine failed to respond, whereas 4 other no-takes receiving diluted vaccine, and 4 receiving undiluted vaccine, mounted an antibody response. Interestingly, their antibody profiles were not significantly different from controls that did show a take. However, we did find elevated antibody titers in no-takes prior to receiving DryVax® that was significantly different from takes. Although the sample size studied was small, we conclude the failure to take in responders correlates with pre-existing immunity of unknown etiology that may attenuate the skin reaction in a way similar to previous smallpox vaccination. Antibody profiling was peformed on sera from vaccinees receiving smallpox vaccines, either Wyeth DryVax or Aventis Pasteur Vaccine ('WetVax') in NIH-sponsored clinical trials. These samples comprise 23 vaccinia naïve no-takes, and 50 vaccinia naïve takes and 25 previoulsy vaccinated takes as controls. Samples from d0 (day of vaccination) and at the peak of the antibody repsonse (d28) were taken from each donor and probed in triplicate against the proteome arrays.

2012-01-09 | E-GEOD-34931 | biostudies-arrayexpress

Smallpox vaccination with LC16m8 vaccinia virus provides a gene expression profile similar to DryVax vaccination

Project description:Transcriptional analysis of global gene expression changes in naïve subjects in response to smallpox vaccination with either DryVax or the replication-competent, attenuated LC16m8 vaccinia virus. Subjects were vaccinated with either DryVax or LC16m8 (5 from each group), and blood samples were taken at days 0, 3, 7, 10, 13, and 21 post-vaccination. PBMCs were isolated from the samples, and were then further separated into cell subpopulations using positive selection against CD markers (CD4+, CD20+). There are a total of 142 samples analyzed in this dataset.

2010-12-01 | E-GEOD-22121 | biostudies-arrayexpress

Influenza Vaccination Primes Human Myeloid Cell Cytokine Secretion and Natural Killer Cell Function

Project description:51 healthy adults were vaccinated with seasonal influenza vaccine and PBMC were collected before and up to 30 days after vaccination and myloid and lymphoid (NK) cell function in response to restimulation with IL-15 alone virus was assessed.

2019-08-31 | GSE133478 | GEO

Ribosome quality control activity potentiates vaccinia virus protein synthesis during infection

Project description:Viral infection both activates stress signaling pathways and redistributes ribosomes away from host mRNAs to translate viral mRNAs. The intricacies of this ribosome shuffle from host to viral mRNAs are poorly understood Here, we uncover a role for the ribosome associated quality control (RQC) factor, ZNF598, during vaccinia virus mRNA translation. ZNF598 acts on collided ribosomes to ubiquitylate 40S subunit proteins uS10 and eS10 initiating RQC-dependent nascent chain degradation and ribosome recycling We show that vaccinia infection in human cells enhances uS10 ubiquitylation indicating an increased burden on RQC pathways during viral propagation. Consistent with an increased RQC demand, we demonstrate that vaccinia virus replication is impaired in cells which either lack ZNF598 or express a ubiquitylation deficient version of uS10 Using SILAC-based proteomics and concurrent RNAseq analysis, we determine that translation and not transcription of vaccinia virus mRNAs is compromised in cells with deficient RQC activity. Additionally, vaccinia virus infection reduces cellular RQC activity, suggesting that co-option of ZNF598 by vaccinia virus plays a critical role in translational reprogramming that is needed for optimal viral propagation.

2021-04-14 | GSE165732 | GEO

Safety Study of Modified Vaccinia Virus to Cancer

Project description:The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.

| 2047624 | ecrin-mdr-crc

Vaccinia virus WR strain:WR

Project description:Vaccinia virus raw sequence reads

| PRJNA280609 | ENA

Identification of Vaccinia Virus HLA Class I Peptides Presented by the Immune System

Project description:Seeking to identify HLA class I peptides that originate from vaccinia virus proteins to understand the mechanism of immune protection. Note that vaccinia-infected B cells will still continue to present (primarily) a wide variety of peptides originating from endogenous proteins; this data set contains evidence for more than 5000 such peptides. The objective and challenge is to detect and identify the peptides that originate from the pathogen (vaccinia virus) in the presence (background) of this large number of endogensous 'self' peptides. Keywords: Peptide search results from multiple injections of multiple strong cation exchange fractions combined into one set of results.

2009-08-31 | GSE10549 | GEO

Vaccinia virus Copenhagen

Project description:High frequency single nucleotide changes and copy number amplification support rapid evolution of vaccinia virus

| PRJNA317676 | ENA